[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin ) (Axumin)
Multimodality 18F-Fluciclovine PET, MRI and Cell Free Circulating DNA to Differentiate Tumor Progression From Pseudoprogression in Patients With Glioblastoma
Sponsor: Ali Nabavizadeh
This PHASE1 trial investigates Glioma Glioblastoma Multiforme and is currently completed. Ali Nabavizadeh leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2022 — Apr 2023 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Apr 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Apr 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Jun 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ali Nabavizadeh
- Blue Earth Diagnostics
For direct contact, visit the study record on ClinicalTrials.gov .